Blueprint Medicines Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 15, 2024 at 07:00 am EST
Share
Blueprint Medicines Corporation reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 71.96 million compared to USD 38.78 million a year ago. Net loss was USD 110.92 million compared to USD 158.64 million a year ago. Basic loss per share from continuing operations was USD 1.82 compared to USD 2.65 a year ago. Diluted loss per share from continuing operations was USD 1.82 compared to USD 2.65 a year ago.
For the full year, revenue was USD 249.38 million compared to USD 204.04 million a year ago. Net loss was USD 506.98 million compared to USD 557.52 million a year ago. Basic loss per share from continuing operations was USD 8.37 compared to USD 9.35 a year ago. Diluted loss per share from continuing operations was USD 8.37 compared to USD 9.35 a year ago.
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.